@article{6158ba495aa64b43b3edbc52e17fe12d,
title = "Innate immune responses in swine resuscitated from severe traumatic hemorrhagic shock with hemoglobin-based oxygen carrier-201",
abstract = "Hemoglobin-based oxygen carrier-201 transports oxygen and improves survival in swine with hemorrhagic shock, but has potential to be immune activating. Herein, we evaluated HBOC-201's immune effects in swine with more severe hemorrhagic shock due to soft tissue injury and 55% blood volume catheter withdrawal over 15 minutes followed by fluid resuscitation at 20 minutes with HBOC-201, Hextend, or no treatment (NON) before hospital arrival. Survival rates were similar with HBOC-201 and Hextend (p > 0.05), but were higher than in (p = 0.007). There were no significant group differences in blood cell count, percentages of leukocyte sub-populations and immunophenotype (CD4:CD8 ratio), adhesion markers expression (neutrophil CD11b; monocyte or neutrophil CD49d) and apoptosis. There was a trend to higher plasma IL-10 in HBOC-201 and groups vs. Hextend. We conclude that in swine with severe controlled HS and soft tissue injury, immune responses are similar with resuscitation with HBOC-201 and Hextend.",
keywords = "Adhesion markers, Apoptosis, Cytokines, HBOC-201, Hemorrhagic shock, Hextend, Resuscitation, Trauma",
author = "C. Hall and N. Malkevich and M. Handrigan and C. VanderMolen and F. Aranaud and J. Hong and F. Dong and J. Rice and N. Philbin and S. Ahlers and R. McCarron and D. Freilich and G. McGwin and Flournoy, {W. S.} and Pearce, {L. Bruce}",
note = "Funding Information: The authors thank HM1 Benjamin Esperat, Ms. Noemy Carballo, Mr. Michael Hammet and Ms. Shruti Naik for their excellent technical support. The studies described herein were entirely funded by the U.S. Government, Office of Naval Research, Work Unit Number 602236N.4426.W26.A0241. Hextend was provided by Abbott Laboratories to Naval Medical Research Center (NMRC) researchers at no cost (under a Materials Transfer Agreement). Dr. L. Bruce Pearce is an employee of Biopure Corp. and has financial interest in the subject material, HBOC-201. Dr. Pearce{\textquoteright}s contribution to the manuscript was limited to editing of the study design, protocol and manuscript. NMRC and Biopure Corp. have a Cooperative Research and Development Agreement for the evaluation of HBOC-201 in trauma clinical trials and a Materials Transfer Agreement for the supply of HBOC for pre-clinical studies. There are no funds transferred from Biopure to NMRC in either of these agreements.",
year = "2007",
month = may,
doi = "10.1080/10731190701378568",
language = "English",
volume = "35",
pages = "259--274",
journal = "Artificial Cells, Blood Substitutes, and Biotechnology",
issn = "1073-1199",
number = "3",
}